（股份代號：2453） 自願公告 與大興發展租賃達成融資合作 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發，以知會本公司股東及潛在投資者有關本集團的最新業務發展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 通過與專業融資租賃公司合作，本公司將進一步拓展融資管道，豐富公司的資金 來源，為未來業務發展中的資金需求提供更多保障，同時也有助於公司與行業內 專業機構建立長期合作關係，為後續合作奠定基礎。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生；及(iii) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 基石 藥業將攜 C S 2 0 1 5 （ O X 4 0 L / T S L P雙特 異性抗體 ）亮相 A C A A I 2 0 2 5 本公告乃由基石藥業(「本公司」連同其附屬公司統稱(「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 …………………………………………………………………………………………… 基石藥業今日宣佈公司自身免疫與炎症領域管線之一CS2015（ ...

Group 1 - The pharmaceutical sector has outperformed the market, with stock prices increasing between 60% to 100% in the first half of the year [1] - The export value of innovative drugs in the first half of the year has already reached the total amount of the previous year [1] - The stock price of CSPC Pharmaceutical Group (01093) has shown strong performance, reaching HKD 10.27, up 6.10% with a trading volume of HKD 14.29 billion [2] Group 2 - Technical indicators for CSPC indicate a bullish trend, with MACD maintaining a buy signal and RSI rising to 61, entering a strong zone [2] - Key price levels for CSPC include a psychological support at HKD 9 and a short-term target at HKD 10.42, with a potential challenge at HKD 11.4 [2] - The performance of related derivatives has shown significant leverage effects, with call warrants outperforming the underlying stock [4] Group 3 - Two notable call warrants for CSPC are available: one with a strike price of HKD 10.88 and a leverage of 3.6 times, and another with a strike price of HKD 10.95 and a leverage of 3.1 times [7] - Investors are considering whether the recent price increase for CSPC is a short-term rebound or the start of a medium to long-term trend [9]

Group 1 - The Hang Seng Index (HSI) has seen bearish investors continuously for three days, indicating a potential decline for at least a week, with a recall price of 24,498 for bear certificates [1] - Investors are deploying bull certificates towards the end of trading sessions, betting on the next day's market movements, which reflects a common overnight holding strategy [2] - Technical analysis suggests that the HSI is currently above 24,000, with support at 23,618 and resistance at 24,542, indicating a "buy" signal [2] Group 2 - Hua Hong Semiconductor (01347.HK) has a strong buy signal, with resistance levels at 38.6 and 41.5, while investors are eyeing a potential rise to 44 [4] - WuXi Biologics (02269.HK) is stabilizing at a closing price of 25.65, with neutral technical signals and resistance at 26.8 and 29, while support is at 23.9 [7] - BYD Electronic (00285.HK) shows a buy signal, with a target of 40, but requires breaking through resistance levels at 32.8 and 33.9 [10] Group 3 - Meituan-W (03690.HK) has bearish investors anticipating a drop below 90 before entering the market, with some considering put options [12] - NetEase-S (09999.HK) is on an upward trend, with resistance at 219 and 229, while investors are cautious about the safety of a bear certificate with a recall price of 220 [14]

Investment Rating - The investment rating for the company is set at ★★★☆☆ [5] Core Insights - The company is a key leader in the global antibody-drug conjugate (ADC) field, focusing on developing innovative ADC drugs for cancer and autoimmune diseases [1] - The company has established four global innovative ADC technology platforms, with the DITAC platform showing a broad therapeutic window, potentially improving efficacy and safety in clinical settings [2] - The ADC market has shown significant growth, expanding from USD 2 billion in 2018 to USD 10.4 billion in 2023, with a projected compound annual growth rate (CAGR) of 38.6% [4] Summary by Sections Company Overview - The company has two core products: DB-1303/BNT323, targeting HER2 for cancers like endometrial and breast cancer, and DB-1311/BNT324, targeting B7-H3 for cancers such as small cell lung cancer and prostate cancer [1] Technology Platforms - The DITAC platform targets topoisomerase, an enzyme crucial for DNA replication and transcription, indicating potential for treating various solid tumors by inducing DNA damage in cancer cells [2] Clinical Trials and Partnerships - The company is conducting seven global multi-regional clinical trials across 230 clinical trial centers in 17 countries, with over 2,000 patients enrolled [3] - Strategic partnerships have been established with leading biopharmaceutical companies, including BioNTech and GSK, with a total transaction value exceeding USD 6 billion [3] Market Potential - The ADC market is expected to continue strong growth, with projections of reaching USD 115.1 billion by 2032, driven by increasing exploration in non-oncological indications [4] Financial Data - For the fiscal year ending December 31, 2023, the company reported other income of RMB 1.787 billion and a shareholder loss of RMB 358 million, with projections for 2024 showing an increase in other income to RMB 1.941 billion and a deeper loss of RMB 1.050 billion [5]